english.prescrire.org > Prescrire International > N°174 - September 2016

n°174

September 2016

Issue Contents
Editorial

Free  Tooth and nail

p.200
Protecting public health from big pharma's greed

New Products


Evolocumab (Repatha°)

p.201-205
A "mab" for hypercholesterolaemia: no evidence of benefits

Panacea-mAb

p.203

50 years of cholesterol-regulating drugs: what benefits?

p.205

Alirocumab (Praluent°)

p.206
Another cholesterol-lowering "mab" with no evidence of efficacy

INN common stem: -triptan

p.206

Insulin glargine 300 U/ml (Toujeo°)

p.207
An anti-generic strategy that creates confusion

Ceritinib (Zykadia°) and non-small cell lung cancer

p.208
Yet another cancer drug authorised despite incomplete evaluation

Adverse Effects


Citalopram, escitalopram and QT prolongation

p.209-211
Consistent data

Citalopram, escitalopram: overdoses are more serious than with other SSRIs

p.211

Drug-induced tendon damage

p.212-213
Fluoroquinolones, statins, steroids

Six tablets of an NSAID: closure of the ductus arteriosus and emergency Caesarean section

p.214

Mercaptopurine: massive ingestion and poisoning in a child

p.214

Neuroleptics: pneumonia in young adults too

p.214

Free  Mizolastine: prefer cetirizine or loratadine

p.215

Free  Dextromethorphan: neurological disorders in children

p.215

Free  Desloratadine, loratadine: aggression

p.215

Reviews


Oral treatment of iron-deficiency anaemia in adults

p.216-219
Attention to detail makes supplementation more tolerable

Helping patients limit the adverse effects of oral iron

p.218
Prescrire's proposal

Pregnant women with interdigital fungal foot infection

p.219-220

Outlook


Free  The Council of Europe upholds the primacy of public health interests over industry interests

p.221-222
Alternatives to patent-based innovation and sponsored CME are needed

Free  How to guarantee the primacy of public health interests?

p.222

Free  "Adaptive pathways"

p.223
EMA' s dangerous plan

Masthead


Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe